GlobeNewswire: Shire Pharmaceuticals Group Contains the last 10 of 222 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T01:47:44ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/12/01/1660399/0/en/Initial-Data-from-Shire-Collaboration-Identifies-Key-Biomarkers-That-Affect-Bleeding-Patterns-Response-to-Treatment-for-Hemophilia-A.html?f=22&fvtc=4&fvtv=35243Initial Data from Shire Collaboration Identifies Key Biomarkers That Affect Bleeding Patterns, Response to Treatment for Hemophilia A2018-12-01T17:00:44Z<![CDATA[Initial Data from Shire Collaboration Identifies Key Biomarkers That Affect Bleeding Patterns, Response to Treatment for Hemophilia A]]>https://www.globenewswire.com/news-release/2018/08/03/1546806/0/en/Shire-plc-Rule-2-9-Announcement.html?f=22&fvtc=4&fvtv=35243Shire plc : Rule 2.9 Announcement2018-08-03T06:01:15Z<![CDATA[NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.]]>https://www.globenewswire.com/news-release/2018/08/02/1545990/0/en/Shire-plc-Rule-2-9-Announcement.html?f=22&fvtc=4&fvtv=35243Shire plc : Rule 2.9 Announcement2018-08-02T06:01:35Z<![CDATA[NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.]]>https://www.globenewswire.com/news-release/2018/08/01/1545212/0/en/Shire-plc-Total-voting-rights.html?f=22&fvtc=4&fvtv=35243Shire plc : Total voting rights2018-08-01T09:01:05Z<![CDATA[Total Voting Rights]]>https://www.globenewswire.com/news-release/2018/08/01/1545156/0/en/Shire-plc-Half-year-Report.html?f=22&fvtc=4&fvtv=35243Shire plc : Half-year Report2018-08-01T06:01:18Z<![CDATA[Half-yearly Report]]>https://www.globenewswire.com/news-release/2018/08/01/1545150/0/en/Shire-plc-Rule-2-9-Announcement.html?f=22&fvtc=4&fvtv=35243Shire plc : Rule 2.9 Announcement2018-08-01T06:01:02Z<![CDATA[NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.]]>https://www.globenewswire.com/news-release/2018/07/31/1544473/0/en/Shire-plc-2nd-Quarter-Results.html?f=22&fvtc=4&fvtv=35243Shire plc : 2nd Quarter Results2018-07-31T11:01:28Z<![CDATA[]]>https://www.globenewswire.com/news-release/2018/07/30/1543650/0/en/Shire-plc-Miscellaneous.html?f=22&fvtc=4&fvtv=35243Shire plc : Miscellaneous2018-07-30T06:01:03Z<![CDATA[NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.]]>https://www.globenewswire.com/news-release/2018/07/26/1542410/0/en/Shire-plc-Rule-2-9-Announcement.html?f=22&fvtc=4&fvtv=35243Shire plc : Rule 2.9 Announcement2018-07-26T06:00:48Z<![CDATA[NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.]]>https://www.globenewswire.com/news-release/2018/07/25/1542018/0/en/Shire-plc-Director-Declaration.html?f=22&fvtc=4&fvtv=35243Shire plc : Director Declaration2018-07-25T14:31:03Z<![CDATA[Director Declaration]]>